Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

Journal of the National Cancer Institute - 15 Jun 2005

Haas-Kogan Daphne A, Prados Michael D, Tihan Tarik, Eberhard David A, Jelluma Nannette, Arvold Nils D, Baumber Rachel, Lamborn Kathleen R, Kapadia Ami, Malec Mary, Berger Mitchel S, Stokoe David

Abstract excerpt

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Erlotinib Hydrochloride

Share to Phosphoric Monoester Hydrolases

Share to PTEN Phosphohydrolase

Share to Quinazolines

Share to Temozolomide

Source

Identifiers

PMID: 15956649
DOI: 10.1093/jnci/dji161

Genes

EGFR
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.PMID 15956649Read ↗

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.Semantic proximity Read ↗

Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.Semantic proximity Read ↗

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.Semantic proximity Read ↗

Targeting the AKT Pathway in GlioblastomaSemantic proximity Read ↗

Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaSemantic proximity Read ↗

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor responseSemantic proximity Read ↗

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.Semantic proximity Read ↗

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.Semantic proximity Read ↗

Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.Semantic proximity Read ↗

Activation of ERBB4 in glioblastoma can contribute to increased tumorigenicity and influence therapeutic responseSemantic proximity Read ↗

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.